Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adultsAdam J. Lamble, Shannon L. Maude, Liora M. Schultz et al.|Blood Advances|2024Cited by 32
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Rawan Faramand, Gregory W. Roloff et al.|Blood Advances|2025Cited by 15
Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia; A Merged Analysis from the Prwcc and PHISPrakash Satwani, Liora M. Schultz, Karen Chao et al.|Blood|2023Cited by 1
Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia: A Merged Analysis from the Pediatric Real-World CAR Consortium (PRWCC) and Pediatric Health Information System (PHIS)Prakash Satwani, Liora M. Schultz, Karen Chao et al.|Transplantation and Cellular Therapy|2024Cited by 0
Liberalizing Requirements for Hospital Proximity Post-CD19 CAR for Children with Low Burden B-ALL at InfusionLauren Appell, Liora M. Schultz, Arunkumar Modi et al.|Transplantation and Cellular Therapy|2025Cited by 0